A Phase II Evaluation of the Poly (ADP-Ribose) Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888) (NSC#737664) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Who Carry a Germline BRCA1 or BRCA2 Mutation

Trial ID # NCT01540565
Phase II
Drug Class DNA Damage Repair Pathway Inhibitors: PARP
Drug Name Veliparib
Alternate Drug Names ABT-888
Drugs in Trial Veliparib
Eligible Participant

Germline BRCA MUT ovarian cancer with ≤ 3 prior therapies; no prior PARP inhibitor treatment

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, PFS, evaluated per RECIST




ORR: 26% (2CR, 11PR)
PFS: 8.18 months

Exploratory analysis Pt status:
Pt-S (n=20): ORR: 35%; PFS: 11.0 months
Pt-R (n=30): ORR: 20%; PFS: 5.8 months

Clinically Significant Adverse Events

Serious AE: none
Grade 3-4 AE: fatigue (6%), nausea (4%)


Encouraging activity in gBRCA MUT ovarian cancer


Coleman RL et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol (2015) 137(3):386-91

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.